Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Type
Public
HQ
Rockville, US
Founded
1996
Employees
159 (est)+99%
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Locations

Rockville, US
Kita Ward, JP
Zug, CH
Chiyoda, JP
Chuo Ward, JP
Sanda-shi, JP
Milton, GB

Sucampo Pharmaceuticals Metrics

Sucampo Pharmaceuticals Summary

Market capitalization

$535 M

Closing share price

$12.6
Sucampo Pharmaceuticals's current market capitalization is $535 M.

Sucampo Pharmaceuticals Financials

Sucampo Pharmaceuticals's revenue is $153 M in FY, 2015 which is 32.68% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$89.6 M$115 M$153 M

Gross profit

$77.2 M$99.2 M$116 M

Operating income

$9.2 M$27.2 M$44.5 M

Operating expense total

$68 M$72 M$72 M

Net Income

$6.42 M$13.1 M$33.4 M

Operating cash flow

$-7.92 M$27.5 M$36.7 M

    Sucampo Pharmaceuticals Market Value History

    Sucampo Pharmaceuticals Online Presence

    Sucampo Pharmaceuticals News

    Sucampo Pharmaceuticals Company Life

    You may also be interested in